Inconsistent conclusions on QoL outcomes from the same clinical trial

Lange, Stefan; Gaertner, Jan; McGauran, Natalie; Schmacke, Nobert; Weingärtner, Vera
January 2016
Gastric Cancer;Jan2016, Vol. 19 Issue 1, p318
Academic Journal
A letter to the article is presented in response to the article "Quality of Life of Older Adult Patients Receiving Docetaxel-based Chemotherapy Triplets for Esophagogastric Adenocarcinoma: A Randomized Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)," by M. Kripp et al that was published in a 2014 issue.


Related Articles

  • Reply to the Letter to the Editor. Kripp, Melanie; Al-Batran, Salah-Eddin; Hofheinz, Ralf-Dieter // Gastric Cancer;Jan2016, Vol. 19 Issue 1, p320 

    A letter by Melanie Kripp et al to a letter to the editor about their article "Quality of Life of Older Adult Patients Receiving Docetaxel-based Chemotherapy Triplets for Esophagogastric Adenocarcinoma: A Randomized Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)" that was...

  • Phase I/II trial of triplet regimen with docetaxel, oxaliplatin and capecitabine in advanced gastric and gastroesophageal cancers. Eswaran, Prasad; Kannan, Kalaichelvi; Narasimhan, Srinivasan Lakshmi; Balaji; Kumar, Suresh; Mavalavan, Durai // Clinical Cancer Investigation Journal;Jul-Aug2015, Vol. 4 Issue 4, p504 

    Background: Advanced and metastatic gastric cancers present at late stages and have very dismal prognosis. Many modifications have been tried for improving the outcome. Docetaxel, cisplatin and fluorouracil/epirubicin, cisplatin and fluorouracil regimen have been established as a standard...

  • Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Lorenzen, S.; Thuss-Patience, P.; Al-Batran, S. E.; Lordick, F.; Haller, B.; Schuster, T.; Pauligk, C.; Luley, K.; Bichev, D.; Schumacher, G.; Homann, N. // Annals of Oncology;Aug2013, Vol. 24 Issue 8, p2068 

    Background The aim of this study was to evaluate the impact of pathologic complete response (pCR) on outcome in patients with gastric or esophagogastric junction (EGJ) adenocarcinoma after neoadjuvant docetaxel/platin/fluoropyrimidine-based chemotherapy. Patients and methods Patients received at...

  • Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer. Burtness, B.; Gibson, M.; Egleston, B.; Mehra, R.; Thomas, L.; Sipples, R.; Quintanilla, M.; Lacy, J.; Watkins, S.; Murren, J. R.; Forastiere, A. A. // Annals of Oncology;Jul2009, Vol. 20 Issue 7, p1242 

    Background: Preclinical evidence suggests synergy between docetaxel and irinotecan, two drugs active in esophagogastric cancer. We previously demonstrated the safety of docetaxel 35 mg/m2 and irinotecan 50 mg/m2 given on days 1 and 8 of a 21-day schedule.

  • Variation in gastroscopy rate in English general practice and outcome for oesophagogastric cancer: retrospective analysis of Hospital Episode Statistics. Shawihdi, Mustafa; Thompson, Elizabeth; Kapoor, Neil; Powell, Geraint; Sturgess, Richard P.; Stern, Nick; Roughton, Michael; Pearson, Michael G.; Bodger, Keith // Gut;Feb2014, Vol. 63 Issue 2, p250 

    Objective To determine whether variation in gastroscopy rates in English general practice populations is associated with inequality in oesophagogastric (OG) cancer outcome. Design Retrospective observational study of the Hospital Episode Statistics (HES) dataset for England (2006-2008) linked to...

  • Minimally Invasive Esophagectomy/Gastroesophagectomy for Cancer. Is it Safe in Nepalese Context? Thakur, Binay; Li Hui; Devkota, Mukti; Chen Xin; Lama, Robin // Journal of Cancer Science & Therapy;2012, Vol. 4 Issue 4, p102 

    Background: Minimally invasive approach for cancer of esophagus and gastroesophageal junction (GEJ) is gaining more popularity in the developed world mainly because of its better cosmetic results, lesser pain and lesser postoperative stay without compromising the radicality of the cancer surgery...

  • Capecitabine and oxaliplatin beneficial in esophagogastric cancer. Kozuch, Peter // Hem/Onc Today;2/10/2008, Vol. 9 Issue 2, p30 

    The article discusses a study of the efficacy of capecitabine and oxaliplatin in the treatment of esophagogastric cancer, which was published in the "New England Journal of Medicine." Results showed a median survival time of 9.9 months for patients administered epirubicin and cisplatin with...

  • Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. Petrioli, Roberto; Francini, Edoardo; Roviello, Franco; Marrelli, Daniele; Fiaschi, Anna; Laera, Letizia; Rossi, Giulia; Bianco, V.; Brozzetti, S.; Roviello, Giandomenico // Cancer Chemotherapy & Pharmacology;May2015, Vol. 75 Issue 5, p941 

    Purpose: The aim of this study was to evaluate the activity and safety of epirubicin (EPI), oxaliplatin (l-OHP) and 5fluorouracil (5FU) (EOF) followed by docetaxel (D), l-OHP and 5FU (DOF) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer. Methods: Forty-five patients...

  • NEWS.  // JNCI: Journal of the National Cancer Institute;1/2/2013, Vol. 105 Issue 1, p4 

    The article presents Physician Data Query (PDQ) summaries that were recently updated. They include the PDQ Esophageal Cancer Treatment summary to include results from a study of patients with resectable esophageal or gastroesophageal junction cancers. Another is the PDQ Ewing Sarcoma Treatment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics